or Try an Advanced Search...

    Technical Analysis for KNSA - Kiniksa Pharmaceuticals, Ltd.

    Grade Last Price % Change Price Change
    D 16.91 0.18% 0.03
    KNSA closed up 0.18 percent on Friday, April 19, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Apr 30
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical KNSA trend table...
    Date Alert Name Type % Chg
    Doji - Bullish? Reversal 0.00%
    Outside Day Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction 0.18%
    Narrow Range Bar Range Contraction 0.18%
    Oversold Stochastic Weakness 0.18%
    Expansion Breakdown Bearish Swing Setup -0.24%
    Oversold Stochastic Weakness -0.24%
    200 DMA Resistance Bearish -3.15%
    Narrow Range Bar Range Contraction -3.15%
    Older End-of-Day Signals for KNSA ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 12 hours ago
    Rose Above Previous Day's High about 16 hours ago
    Outside Day about 16 hours ago
    Fell Below Previous Day's Low about 16 hours ago
    Down 1% about 16 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    KNSA Chart by TradingView
    Basic chart:

    Profile

    Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Disease Medication Pharmacology

    Is KNSA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 2 Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
    Mar 1 Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
    Mar 1 Kiniksa Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
    Mar 1 Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)
    Feb 29 Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice
    Feb 29 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript
    Feb 28 Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript
    Feb 28 Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
    Feb 28 Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023
    Feb 28 Kiniksa Pharmaceuticals GAAP EPS of $0.35 beats by $0.49, revenue of $83.4M beats by $11.13M
    See more KNSA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.09
    52 Week Low 10.65
    Average Volume 382,506
    200-Day Moving Average 17.63
    50-Day Moving Average 19.46
    20-Day Moving Average 18.29
    10-Day Moving Average 17.35
    Average True Range 0.57
    RSI (14) 26.47
    ADX 30.92
    +DI 12.30
    -DI 33.78
    Chandelier Exit (Long, 3 ATRs) 18.60
    Chandelier Exit (Short, 3 ATRs) 18.28
    Upper Bollinger Bands 20.55
    Lower Bollinger Band 16.02
    Percent B (%b) 0.2
    BandWidth 24.76
    MACD Line -0.75
    MACD Signal Line -0.64
    MACD Histogram -0.1087
    Fundamentals Value
    Market Cap 598.78 Million
    Num Shares 35.4 Million
    EPS -0.11
    Price-to-Earnings (P/E) Ratio -153.73
    Price-to-Sales 5.38
    Price-to-Book 3.52
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.79
    Resistance 3 (R3) 17.77 17.46 17.64
    Resistance 2 (R2) 17.46 17.23 17.47 17.59
    Resistance 1 (R1) 17.18 17.10 17.32 17.20 17.54
    Pivot Point 16.87 16.87 16.94 16.88 16.87
    Support 1 (S1) 16.60 16.65 16.74 16.62 16.28
    Support 2 (S2) 16.29 16.51 16.30 16.23
    Support 3 (S3) 16.01 16.29 16.18
    Support 4 (S4) 16.03